The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma

被引：16

作者：

Tsai, Huei-Ting ^{[1
]}

Pfeiffer, Ruth M. ^{[1
]}

Warren, Joan ^{[2
]}

Wilson, Wyndham ^{[3
]}

Landgren, Ola ^{[3
,4
]}

机构：

[1] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NCI, Div Canc Control & Populat Sci, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[3] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 03期

关键词：

Cardiovascular disease; doxorubicin; rituximab; elderly cardiac failure; prognosis; survival; outcome; NON-HODGKINS-LYMPHOMA; SEER-MEDICARE DATA; RISK-FACTORS; PHASE-II; DOXORUBICIN; CHEMOTHERAPY; RITUXIMAB; EPOCH; CARDIOMYOPATHY; MULTICENTER;

D O I：

10.3109/10428194.2014.921914

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We identified 3910 elderly (>65 yrs) patients with diffuse large B-cell lymphoma (DLBCL) who received doxorubicin-based (+/-rituximab) therapy and 77 347 cancer-free controls, and assessed cardiovascular events and survival in relation to preexisting cardiovascular comorbidities. Compared to controls, patients with DLBCL had a 3.4-fold (95% CI 3.0-3.9) and 2.5-fold (95% CI 2.3-2.7) increased risk of congestive heart failure (CHF)/cardiomyopathy (CM) within 6 months and 3 years of diagnosis, respectively. Risk of acute myocardial infarction (AMI) was similarly increased. The risk of CHF/CM and AMI was significantly higher in those patients with DLBCL (vs. controls) who did not report preexisting cardiovascular disease, compared to those who had preexisting cardiovascular disease; this was due to dose reductions of doxorubicin among patients with preexisting cardiovascular disease. Rituximab improved survival in patients with stage III-IV (but not I-II) disease (p-interaction=0.0003). Our novel findings emphasize the need to reduce cardiac toxicity of doxorubicin in elderly DLBCL patients.

引用

页码：682 / 687

页数：6

共 50 条

[21] Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma [J].

Wilson, Wyndham H. ;

Bromberg, Jacoline E. C. ;

Stetler-Stevenson, Maryalice ;

Steinberg, Seth M. ;

Martin-Martin, Lourdes ;

Muniz, Carmen ;

Manuel Sancho, Juan ;

Dolores Caballero, Maria ;

Davidis, Marjan A. ;

Brooimans, Rik A. ;

Sanchez-Gonzalez, Blanca ;

Salar, Antonio ;

Gonzalez-Barca, Eva ;

Maria Ribera, Jose ;

Shovlin, Margaret ;

Filie, Armando ;

Dunleavy, Kieron ;

Mehrling, Thomas ;

Spina, Michele ;

Orfao, Alberto .

HAEMATOLOGICA, 2014, 99 (07) :1228-1235

[22] Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era [J].

Mounier, Nicolas ;

Gisselbrecht, Christian .

CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) :209-213

[23] Management strategies in patients with diffuse large B-cell lymphoma and severe haemophilia [J].

Rutherford, S. C. ;

Martin, P. ;

Chapin, J. .

HAEMOPHILIA, 2015, 21 (05) :E445-E447

[24] Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome [J].

Vannata, Barbara ;

Conconi, Annarita ;

Winkler, Jonas ;

Cascione, Luciano ;

Casaluci, Gloria Margiotta ;

Nassi, Luca ;

Moia, Riccardo ;

Pirosa, Maria Cristina ;

Moccia, Alden A. ;

Stathis, Anastasios ;

Rossi, Davide ;

Gaidano, Gianluca ;

Zucca, Emanuele .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (04) :478-487

[25] Relapsed Diffuse Large B-Cell Lymphoma: Clinical Utility of Cell of Origin [J].

Vose, Julie M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4065-4066

[26] Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry [J].

Nair, Reena ;

Bhurani, Dinesh ;

Rajappa, Senthil ;

Kapadia, Asha ;

Reddy Boya, Rakesh ;

Sundaram, Subramanian ;

Menon, Hari ;

Raman, Ganapathi S. ;

Seshachalam, Arun ;

Nimmagadda, Ramesh .

FRONTIERS IN ONCOLOGY, 2022, 11

[27] Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria [J].

Aribi, Mourad ;

Mesli, Naima ;

Remla, Nesrine ;

Sari, Badr-Eddine ;

Taleb, Abdesselam ;

Touhami, Hadj ;

Bakadja, Mohamed Amine ;

Zouaoui-Benhadji, Zahia ;

Bouzid, Kamel ;

Meguenni, Kaoual .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2010, 6 (01) :41-46

[28] Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results [J].

Adiyaman, Suleyman Cem ;

Alacacioglu, Inci ;

Danyeli, Ayca Ersen ;

Turkyilmaz, Dogus ;

Sevindik, Omur Gokmen ;

Demirkan, Fatih ;

Piskin, Ozden ;

Ozcan, Mehmet Ali ;

Undar, Bulent ;

Ozkal, Sermin ;

Ozsan, Guner Hayri .

TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (02) :81-87

[29] Diffuse large B-cell lymphoma [J].

Barraclough, Allison ;

Hawkes, Eliza ;

Sehn, Laurie H. ;

Smith, Sonali M. .

HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)

[30] Diffuse large B-cell lymphoma [J].

Martelli, Maurizio ;

Ferreri, Andres J. M. ;

Agostinelli, Claudio ;

Di Rocco, Alice ;

Pfreundschuh, Michael ;

Pileri, Stefano A. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) :146-171

← 1 2 3 4 5 →